• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Diseases and Therapy >Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
【24h】

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants

机译：在医疗保险和商业保险婴儿中使用帕利珠单抗预防门诊呼吸道合胞病毒的趋势

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionPalivizumab is indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk children. Previous palivizumab utilization studies examined prior authorization claims but did not examine utilization within insured populations as a whole. This study describes outpatient palivizumab utilization trends and characterizes high-risk infants receiving palivizumab within Medicaid- and commercially insured populations. MethodsInfants born July 1, 2003 through June 30, 2013 were identified in the MarketScan? Multistate Medicaid and Commercial claims databases. Infants with?≥?18?months of continuous medical insurance enrollment with pharmacy benefits after birth and evidence of chronic lung disease of prematurity (CLDP), congenital heart disease (CHD), or preterm birth without CLDP or CHD were studied. Palivizumab use and demographic and clinical characteristics were measured in infant subgroups. Outpatient palivizumab utilization rates were calculated for each seasonal year (July–June) and for each infant subgroup. ResultsIn total, 29,350 (2.1%) Medicaid-insured and 9589 (2.5%) commercially insured infants received palivizumab and had CLDP, CHD, or were born at? ConclusionPalivizumab use is targeted to a small percentage of infants who are at highest risk of hospitalization for RSV disease. Utilization declined in recent years in both Medicaid- and commercially insured infant groups. Most palivizumab doses were administered from November to March, with most infants receiving?≤?5 doses. FundingAstraZeneca.
机译：简介帕利珠单抗用于预防高危儿童的呼吸道合胞病毒（RSV）感染。先前的帕利珠单抗利用率研究检查了事先的授权要求，但没有检查整个被保险人群的利用率。这项研究描述了门诊帕利珠单抗的利用趋势，并表征了在医疗补助和商业保险人群中接受帕利珠单抗的高危婴儿。方法在MarketScan ？多州医疗补助和商业索赔数据库中识别出2003年7月1日至2013年6月30日出生的婴儿。研究了出生后连续≥18个月并获得药房福利的婴儿，以及有慢性早产儿肺疾病（CLDP），先天性心脏病（CHD）或无CLDP或CHD的早产儿的证据。在婴儿亚组中测量了帕利珠单抗的使用以及人口统计学和临床​​特征。计算每个季节年度（7月至6月）和每个婴儿亚组的门诊帕利珠单抗利用率。结果总共有29,350（2.1％）名获得医疗补助的婴儿和9589名（2.5％）有商业保险的婴儿接受了帕利珠单抗治疗，并患有CLDP，CHD或出生于？结论帕利珠单抗的使用针对的是一小部分因RSV疾病住院风险最高的婴儿。近年来，医疗补助和商业保险婴儿组的利用率均下降。帕利珠单抗的大多数剂量是在11月至3月施用的，大多数婴儿接受的剂量≤5≤。资金阿斯利康。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号